alexa The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Steroids & Hormonal Science

Author(s): Best JH, Lavillotti K, DeYoung MB, Garrison LP

Abstract Share this page

Abstract The objective of this systematic review was to assess the published literature on the effectiveness of exenatide twice daily (exenatide) in clinical practice, specifically its effects on haemoglobin A1c (A1C), fasting glucose (FG), weight, systolic blood pressure (SBP), medication use, hospitalization and cardiovascular disease (CVD) outcomes. A systematic literature search using the MEDLINE database of English language literature published between January 2005 and May 2011 was performed. The review included retrospective or prospective observational studies that included 100 or more patients per treatment group. A total of 15 studies meeting the inclusion criteria were identified. The studies revealed significant reductions of -0.4 to -0.9\% in A1C, -10 mg/dl in FG, -2 to -11 kg in body weight and -2 to -11 mmHg in SBP. Statistically significant reductions in the use or dosage of either oral glucose-lowering medications or insulin after initiating exenatide treatment were found in every observational study that assessed medication changes, including reductions in dosage of up to 75\% in sulphonylureas dosages, 22\% in metformin, 66\% in thiazolidinediones (TZD) or TZD combination therapy and 75\% in prandial insulin. Exenatide-treated patients experienced significantly lower rates of all-cause and CVD-related hospitalization and CVD events than patients treated with other therapies overall. In this review of observational studies, exenatide initiation was associated with significant reductions in clinically relevant outcomes. Improvements in A1C, FG, weight and SBP in the observational studies in this review were consistent with improvements observed in controlled clinical trials. © 2011 Blackwell Publishing Ltd. This article was published in Diabetes Obes Metab and referenced in Journal of Steroids & Hormonal Science

Relevant Expert PPTs

Relevant Speaker PPTs

  • Rasha Mosa
    Effects of growth hormone secretagogue receptor agonist and antagonist in non-obese Type 2 Diabetes MKR mice
    PPT Version | PDF Version
  • Nisreen K Aref
    To compare serum leptin levels in obese women with polycystic ovary syndrome (PCOS) and normal ovulatory obese subjects in Saudi Arabia, and to evaluate the interrelationship between leptin concentration, sex hormones, and insulin resistance.
    PPT Version | PDF Version
  • George R. Bousfield
    Influence of Glycans on Biological Activities of Pituitary Gonadotropins: Follicle-Stimulating and Luteinizing Hormone
    PPT Version | PDF Version
  • P Krishnamoorthy
    Relationship of mineral and hormone profile of bovines with reproductive disorders in organized dairy farms in Karnataka and Tamil Nadu
    PPT Version | PDF Version
  • John Arnold D Souza
    Low levels of pesticides disrupt the pituitary- Gonadal hormone functions and reproductive functions in male rodent model
    PPT Version | PDF Version
  • Martha M Sklavos
    Anti-Müllerian hormone deficiency in females with inherited bone marrow failure syndromes
    PDF Version
  • Fuad Fares
    Developing long acting agonists and antagonists of glycoprotein hormones using gene fusion and gene transfer: From bench to clinics
    PPT Version | PDF Version
  • Paul J. Davis
    Nanotetrac targets the thyroid hormone receptor on integrin αvβ3 on tumor cells to promote apoptosis, disorder cell defense pathways and block angiogenesis
    PPT Version | PDF Version
  • A Martin Gerdes
    Wrong about β-blockers! Wrong about positive inotropes! Wrong about Thyroid Hormone treatment of Heart Failure?
    PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords